Undiagnosed diseases: Needs and opportunities in 20 countries participating in the Undiagnosed Diseases Network International
Domenica Taruscio(Istituto Superiore di Sanità), Manuel Posada de la Paz(Instituto de Salud Carlos III), Claudio Carta(Istituto Superiore di Sanità), Stephen C. Groft(National Institutes of Health), Laura L. Cellai(Istituto Superiore di Sanità), Dario Roccatello(Ospedale San Giovanni Bosco), Saumya S. Jamuar(SingHealth), Vinod Scaria(Institute of Genomics and Integrative Biology), Savino Sciascia, Ratna Dua Puri(Sir Ganga Ram Hospital), Prince Makay(University of Kinshasa), Maleeha Azam(COMSATS University Islamabad), Marco Salvatore(Istituto Superiore di Sanità), Vorasuk Shotelersuk(Thai Red Cross Society), Aimé Lumaka(University of Liège), Guida Landouré(Université des Sciences, des Techniques et des Technologies de Bamako), Vajira H. W. Dissanayake(University of Colombo), Yasemin Alanay(Hacettepe University), Vanessa Romero(Universidad San Francisco de Quito), Ugur Ozbek(Acıbadem University), Helene Cederroth, D. Hettiarachchi(University of Colombo), Oleg Kvlividze, Gianluca Ferrari(Istituto Superiore di Sanità), Claudia Gonzaga‐Jauregui(Duke University), William A. Gahl(National Institutes of Health), Olaf A. Bodamer(Universitätsklinik für Kinder und Jugendpsychiatrie), Roberto Giugliani(Instituto de Biologia Molecular e Celular), Gareth Baynam(Government of Western Australia Department of Health), Béla Melegh(University of Pecs), Eva Maria Cutiongco‐de la Paz(University of the Philippines Manila), Samuel Agyei Wiafe(Ghana Health Service)
Cited by 23
Related Papers
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|803
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
|Nature Genetics|2007|702
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522